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drug iNFormaTioN QuesTioN
Question: what evidence is available on apixaban (Eliquis®) for the primary 
prevention of stroke in patients with atrial fibrillation?
by	Justin	Dang,	Pharm.D.		Candidate,	Class	of	2013,	and	Laura	Tsu,	Pharm.D.,	Assistant	Professor,	Midwestern	
University	College	of	Pharmacy-Glendale	
30 • arizona Journal oF Pharmacy • Fall 2012
Answer:
 
Introduction
Atrial fibrillation is a type of supraventricular tachycardia 
where the atria beat at rates of 400-600 beats/minute and have 
disorganized atrial activation.  Common symptoms of atrial 
fibrillation include tachycardia, palpitations, and worsening of 
heart failure symptoms.  Approximately 2.2 million Americans 
have atrial fibrillation and it is expected to increase to 12-15 
million by 2050.  The prevalence of atrial fibrillation increases 
with age, severity of heart failure, and other cardiovascular 
disease states.1
Atrial fibrillation increases the risk of stroke due to atrial 
stasis and thrombi formation.1 The American College of Chest 
Physicians (ACCP) recommends assessing the stroke risk in 
patients with atrial fibrillation using the CHADS2 scoring system.  
Patients are given two points if they have had a prior stroke or 
transient ischemic attack and one point each if they are > 75 
years of age or have hypertension, diabetes, or congestive heart 
failure.2 The risk of stroke increases for each additional point in 
the CHADS2 score with a 1.9% risk for a score of 0, 2.8% for 
a score of 1, 4.0% for a score of 2, 5.9% for a score of 3, 8.5% 
for a score of 4, 12.5% for a score of 5, and 18.2% for a score of 
6.3 Aspirin can reduce the risk of stroke by 21% compared to no 
therapy, and warfarin can reduce the risk of stroke by one-half 
compared to aspirin.  The ACCP guidelines recommend that 
patients with a score of 0, indicating low risk, should receive no 
therapy, aspirin (75 - 325 mg/day), or aspirin plus clopidogrel.  
Patients with a CHADS2 score of one, indicating intermediate 
risk, should receive oral anticoagulation over aspirin or aspirin 
plus clopidogrel.  Lastly, patients with a CHADS2 score of two or 
greater, indicating high risk, should receive oral anticoagulation.2
Despite the proven efficacy of warfarin and aspirin, 
recommendations for oral anticoagulation now favor the newer 
oral anticoagulants over warfarin.  These novel anticoagulants 
have shown at least equal efficacy to warfarin in preventing 
stroke and systemic embolism in patients with atrial fibrillation, 
but lack warfarin’s limitations, which include a narrow 
therapeutic window, need for frequent monitoring, multiple drug-
drug interactions, and dietary restrictions (especially foods with 
high vitamin K content).  Currently, the ACCP guidelines give 
a higher recommendation to dabigatran, an oral direct thrombin 
inhibitor, over warfarin.  Other emerging oral anticoagulants 
include the factor Xa inhibitors, rivaroxaban and apixaban, 
which target a common point in both the extrinsic and intrinsic 
pathways of the clotting cascade and a primary site for signal 
amplification.4 Factor Xa inhibitors also have the advantage of 
not needing international normalized ratio (INR) monitoring 
and having fewer drug and food interactions than vitamin K 
antagonists, such as warfarin.2,4 
The latest factor Xa inhibitor, apixaban, is currently not 
FDA-approved, but two completed trials have demonstrated 
apixaban’s safety and efficacy compared to aspirin and warfarin 
in preventing stroke and systemic embolism in patients with atrial 
fibrillation.  In addition, three completed trials have demonstrated 
apixaban’s safety and efficacy compared to enoxaparin in patients 
undergoing elective total knee replacement and hip replacement 
surgery, and three ongoing trials are currently investigating 
apixaban’s role in venous thromboembolism (VTE) prophylaxis 
and treatment.5 Apixaban is currently dosed at 2.5 or 5 mg twice 
daily with maximum concentration reached in 1-3 hours for 
stroke prevention in patients with atrial fibrillation.  Apixaban 
is approximately 25% renally excreted and 15% metabolized by 
CYP3A4.   In clinical trials, apixaban has shown no significant 
drug-drug interactions and no adverse effects beyond bleeding.5 
In a search of Medline, two randomized controlled clinical 
trials have investigated the safety and efficacy of apixaban for 
stroke and systemic embolism prevention in patients with atrial 
fibrillation.6,7
 
Clinical Trials
The AVERROES (Apixaban Versus Acetylsalicylic Acid [ASA] 
to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed 
or Are Unsuitable for Vitamin K Antagonist Treatment) trial by 
Connolly et al. compares apixaban 5 mg twice daily with aspirin 
at a dose of 81 to 324 mg daily.  A reduced dose of apixaban 
was used (2.5 mg twice daily) if patients met at least two of the 
following criteria: ≥ 80 years old, weight ≤ 60 kg, or SCr ≥ 1.5 
mg/dL.  The investigators estimated that a total of 5600 patients 
would be needed to have 90% power to detect a 35% relative 
reduction in events, as compared to aspirin.  The trial randomized 
5599 patients with atrial fibrillation who were not taking a 
vitamin K antagonist because it was unsuitable or expected to 
be unsuitable and had at least one risk factor for stroke: prior 
stroke or transient ischemic attack, age > 75 years, hypertension, 
diabetes mellitus, heart failure (New York Heart Association 
class II or higher), left ventricular ejection fraction < 35%, or 
documented peripheral arterial disease.  The primary efficacy 
outcome was the occurrence of stroke (ischemic or hemorrhagic) 
or systemic embolism.  The primary safety outcome was the 
occurrence of major bleeding as defined by the International 
Society of Thrombosis and Haemostasis (ISTH), which includes 
a decrease in hemoglobin level of ≥ 2 g/dL over a 24-hour period, 
transfusion of  ≥ 2 packed red blood cells, bleeding at a critical 
site, or fatal bleeding.6 
The results of this trial showed 51 primary outcome events 
(1.6% per year) for patients on apixaban and 113 events (3.7% 
per year) for patients on aspirin (95% CI, 0.32 to 0.62; P<0.001).  
The rate of death was 3.5% per year for patients on apixaban 
and 4.4% per year for patients on aspirin (95% CI, 0.62 to 
1.02; P=0.07).  There were 44 major bleeding events (1.4% per 
year) for patients on apixaban and 39 events (1.2% per year) 
for patients on apixaban (95% CI, 0.74 to 1.75; P=0.57).  There 
were 188 minor bleeding events for patients on apixaban and 153 
events for patients on aspirin (95% CI, 1.00 to 1.53; P=0.05).  
The composite rate of stroke, systemic embolism, myocardial 
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infarction, death from vascular causes, or major bleeding was 
5.3% per year with apixaban and 7.2% per year with aspirin (95% 
CI, 0.60 to 0.90; P=0.003).  The trial was terminated early for 
efficacy after the first planned interim analysis and confirmatory 
analysis showed a benefit with apixaban over 4 SD (z=4.76) and 
P value of 0.000002.  The authors of this study concluded that 
apixaban reduced the risk of stroke or systemic embolism by 
more than 50% when compared with aspirin without significantly 
increasing the risk of major bleeding.6 
The ARISTOTLE (Apixaban for Reduction in Stroke and 
Other Thromboembolic Events in Atrial Fibrillation) trial by 
Granger et al. compares apixaban 5 mg twice a day with dose-
adjusted warfarin to INR of 2-3.  Similar to the AVERROES 
trial, a reduced dose of apixaban was used (2.5 mg twice daily) if 
patients met at least two of the following criteria: ≥ 80 years old, 
weight ≤ 60 kg, or SCr ≥1.5 mg/dL.  The investigators estimated 
that 18,000 patients would be needed to achieve 90% power to 
show at least a 50% relative risk reduction in stroke and systemic 
embolism compared with warfarin.  The trial randomized 18,201 
patients with atrial fibrillation and at least one other risk factor 
for stroke: prior stroke, transient ischemic attack, or systemic 
embolism; age over 75 years; hypertension (receiving treatment); 
symptomatic heart failure; or left ventricular ejection fraction less 
than 40%.  The primary efficacy outcome was stroke or systemic 
embolism, and the key secondary efficacy outcome was death 
from any cause.  The primary safety outcome was major bleeding 
as defined by ISTH criteria.7
The results of the trial showed the primary outcome occurring 
in 212 patients (1.27% per year) in the apixaban group and 265 
patients (1.60% per year) in the warfarin group (95% CI, 0.66 to 
0.95; P<0.001 for noninferiority and P=0.01 for superiority).  The 
rate of death from any cause was 3.52% per year in the apixaban 
group and 3.94% per year in the warfarin group (P=0.047).  
Major bleeding occurred in 327 patients (2.13% per year) in the 
apixaban group and 462 patients (3.09% per year) in the warfarin 
group.  This includes a lower rate of intracranial hemorrhage with 
apixaban versus warfarin (52 versus 122, P<0.001).  The authors 
of this study concluded that apixaban significantly reduced the 
risk of stroke or systemic embolism by 21%, major bleeding by 
31%, and death by 11% compared with dose-adjusted warfarin.7
 
Discussion
The two clinical trials, AVERROES and ARISTOTLE, 
compared apixaban to aspirin and warfarin, respectively, and 
demonstrated that apixaban significantly reduced the rate of 
stroke in patients with atrial fibrillation and at least one risk 
factor for stroke.  Apixaban was also shown to not significantly 
increase bleeding risk when compared to aspirin and showed 
a significantly decreased risk of bleeding when compared to 
warfarin.6,7
While apixaban appears to be superior to warfarin in terms 
of efficacy and safety, there are no controlled trials that directly 
compare apixaban to the other novel oral anticoagulants, such 
as dabigatran or rivaroxaban.6,7 The ACCP guidelines have been 
revised to favor dabigatran 150 mg twice daily over vitamin K 
antagonists in patients with a CHADS2 score of two or more 
based on the RE-LY (Randomized Evaluation of Long-Term 
Anticoagulation Therapy) trial.2 This study demonstrated that 
dabigatran 150 mg twice daily was superior to warfarin in the 
prevention of stroke and systemic embolism in patients with 
atrial fibrillation and showed no difference in the rates of major 
bleeding.  The lower dose of dabigatran 110 mg twice daily was 
non-inferior to warfarin with respect to prevention of stroke or 
systemic embolism and had a significantly lower incidence of 
major bleeding.8 In the ROCKET AF (Rivaroxaban Once Daily 
Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in 
Atrial Fibrillation) trial, rivaroxaban 20 mg was non-inferior to 
warfarin in terms of stroke and systemic embolism prevention, 
but there were similar rates of major bleeding between the 
two groups.9 This is in comparison to apixaban, which has 
demonstrated superiority in preventing stroke and systemic 
embolism compared to warfarin, without a corresponding 
increase in major bleeding.  However, it is not possible to state 
that apixaban is the preferred anticoagulant because while the 
ARISTOTLE, RE-LY, and ROCKET-AF trials shared similar 
primary efficacy and safety endpoints, the patient populations 
were different.  The main distinction between the trials lies in 
the average CHADS2 score, which was 2.1 in the ARISTOTLE 
trial, 2.2 in the RE-LY trial, and 3.5 in the ROCKET-AF trial.7-9  
The warfarin group in the ROCKET-AF trial also had less 
optimal management of their INR readings, with only 55% of 
patients within therapeutic range during the study, compared to 
62% in ARISTOTLE and 64% in RE-LY.7-9 These factors could 
contribute to the different results from these trials and preclude 
clinicians from making direct comparisons without additional 
real-world data.
In comparison to warfarin, apixaban is similar to the other 
new anticoagulants in that it provides adequate anticoagulation 
without the need for therapeutic monitoring or dietary 
restrictions.  However, the drawbacks to these new agents 
include the lack of a reversal agent, no monitoring parameters 
to determine medication compliance, and multiple daily 
dosing with dabigatran and apixaban.3 There have also been no 
studies evaluating the safety of apixaban in patients with renal 
insufficiency or with long- term use.  Compared to dabigatran and 
rivaroxaban, apixaban offers the advantage of a lower bleeding 
rate, fewer drug interactions, and less gastrointestinal side effects. 
Therefore, apixaban is a promising new anticoagulant that will 
offer an alternative to the currently available options.
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